Innovative Testing Platform HeMemics offers a portable and user-friendly biosensor platform capable of delivering lab-quality results in diverse settings such as farms, clinics, or emergency sites, making it ideal for markets requiring rapid, on-site diagnostics.

Recent Manufacturing Growth With over 100,000 graphene biosensors produced through strategic partnership with General Graphene, the company demonstrates significant manufacturing capacity, presenting opportunities to supply large-scale testing needs across healthcare and industrial sectors.

Strong Funding Momentum Recent successful seed financing rounds totaling $2 million, backed by investors like TEDCO, underscore investor confidence and provide resources to expand sales efforts into new markets and product lines.

Strategic COVID-19 Focus Early collaboration with BARDA on rapid SARS-CoV-2 diagnostics indicates expertise and experience in pandemic-related testing solutions, opening avenues to pitch products to public health agencies and emergency preparedness organizations.

Technology-Driven Differentiation By leveraging graphene-based sensors and Bluetooth-enabled diagnostics, HeMemics positions itself as a cutting-edge provider capable of offering customizable, high-precision testing tools suitable for healthcare, agriculture, and defense sectors, presenting diverse cross-industry sales opportunities.